111 (NASDAQ:YI – Get Free Report) and Outset Medical (NASDAQ:OM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Risk and Volatility
111 has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Outset Medical has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.
Earnings and Valuation
This table compares 111 and Outset Medical”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 111 | $1.80 billion | 0.03 | -$9.65 million | ($1.00) | -5.40 |
| Outset Medical | $119.48 million | 0.68 | -$81.65 million | ($4.16) | -1.06 |
111 has higher revenue and earnings than Outset Medical. 111 is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
21.3% of 111 shares are owned by institutional investors. 43.9% of 111 shares are owned by company insiders. Comparatively, 2.5% of Outset Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares 111 and Outset Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 111 | -0.53% | N/A | -2.72% |
| Outset Medical | -63.65% | -56.13% | -27.45% |
Analyst Ratings
This is a summary of current recommendations for 111 and Outset Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 111 | 1 | 0 | 0 | 0 | 1.00 |
| Outset Medical | 1 | 1 | 3 | 0 | 2.40 |
Outset Medical has a consensus target price of $10.00, indicating a potential upside of 127.79%. Given Outset Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Outset Medical is more favorable than 111.
Summary
111 beats Outset Medical on 8 of the 14 factors compared between the two stocks.
About 111
111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.
About Outset Medical
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Receive News & Ratings for 111 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 111 and related companies with MarketBeat.com's FREE daily email newsletter.
